Compare ACON & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACON | ACXP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.2M |
| IPO Year | 2022 | 2021 |
| Metric | ACON | ACXP |
|---|---|---|
| Price | $2.42 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 43.8K | ★ 79.3K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,730.00 | N/A |
| Revenue This Year | $78.26 | N/A |
| Revenue Next Year | $90.37 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.62 | N/A |
| 52 Week Low | $1.95 | $1.27 |
| 52 Week High | $12.03 | $8.34 |
| Indicator | ACON | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 37.98 |
| Support Level | $2.33 | N/A |
| Resistance Level | $2.50 | $1.46 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 22.95 | 31.58 |
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.